First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Contagious diseases like measles, COVID-19, influenza, norovirus, and tuberculosis pose significant global health challenges.

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.

Health officials have issued a '48-hour' plea to parents following a rise of norovirus cases in recent weeks, particularly ...

Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.

A recent Indian Council of Medical Research (ICMR) study made some shocking revelations. It discovered that one in nine ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...

Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been provided below.

This fall, multiple states including Maryland, Virginia, Tennessee and Wisconsin have reported outbreaks of hand, foot and ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...

Speaking to the Daily Mail, Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, said: 'Supplements ...